baber/WOPTO huggingface dataset:
Patent CS-216893-B1 (CS)
Inventor: PANOCH JULIUS
IPC: C04B41/00
Filed: 1980-12-30
Abstract: Vynález spadá do odboru keramického
priemyslu. Jeho podstatou je, že sa výrobky
obrábajú plynulým přetlačováním medzi nehybnými
režnými hranami funkčných ploch
režných pretlačovacích nástrojov, ktoré obrábajú
operačný prídavok na obrábanie súčasne
z aspoň dvoch protilahlých ploch výrobku.
Zariadenie pozostáva z posuvného
mechanizmu s aspoň jedným unášacím článkom
výrobku na pretláčanie výrobku jeho
protiíahlými obrábanými plochami medzi súbežné
protiiahlé rady dopružovaných symetrizačných
kladiek. V přerušení radov symetrizačných
kladiek sú symetricky po
oboch stranách výrobku umiestnené v linii
s radmi režné pretlačovacie nástroje. Ich
plochy sú opatřené jednou alebo viacerými
hranami pre odoberanie operačného přídavku
v jednej alebo viacerých elementárnych
vrstvách. Z dalších dvoch protilahlých stráň
výrobku je súbežne s radmi symetrizačných
kladiek z jednej strany rad dopružovaných
dotláčacích kladiek pre dotláčanie výrobku
na rad oporných kladiek, ktoré sú z druhej
strany.
Patent CS-252317-B1 (CS)
Inventor: KULOVANY PAVEL
IPC: B64C11/30
Filed: 1985-12-19
Abstract: Vratné zařízení kroužku zpětné vazby
leteckých vrtulí sestává z desky, opatřené
pouzdrem, v němž je umístěna pružina, která
dosedá na náboj vrtule. Deska je přes
nejméně dvě táhla spojena s kroužkem zpětný
vazby. Pružina je uspořádána na vodicí
tyčce, která prochází pouzdrem a je upevněna
v náboji vrtule.
Patent CS-223319-B1 (CS)
Title: Nerozpustná anoda pro galvanické vylučování kovových povlaků, zejména z drahých kovů
Inventor: MRAZ RUDOLF
IPC: C25D17/10
Filed: 1981-12-28
Abstract: Vynález náleží do oboru ochrana kovů proti korozi a řeší zdokonalení anody pro vylučování povlaků z drahých kovů. Anoda podle vynálezu je tvořena kovovým základem opatřeným polovodivým povlakem, sestávajícím z nejméně dvou vrstev odlišných vlastností, tvořených směsí oxidů kovů, náležejících do IV., V. a VIII. skupiny periodického systému prvků. Kovový základ anody je s výhodou tvořen kovem ze skupiny zahrnující titan a tantal a polovodivý povlak je s výhodou tvořen oxidy kovů téže skupiny a oxidy kovů ze skupiny platiny.
Patent DK-172604-B1 (DK)
Inventor: WIERZBICKI MICHEL
IPC: C07C211/42
Filed: 1989-07-04
Granted: 1999-02-22
Abstract: New benzocycloheptene derivatives of general formula: 
<IMAGE>
 in which: - X is hydrogen, C1-C5 alkyl, cyano or hydroxyl, and - X' is: hydroxyl, a radical OR (R being acyl or optionally substituted C1-C5 alkyl), a radical 
<IMAGE>
 [n being zero, one or two, each of R1 and R2, which are identical or different, being: hydrogen, optionally substituted C1-C5 alkyl, C2-C5 alkenyl or alkynyl, or acyl; or R1 and R2 together with the nitrogen atom to which they are bonded denote either: 
<IMAGE>
 Ra being hydrogen or C1-C5 alkyl and Rb: hydrogen, C1-C5 alkyl, phenyl or phenylalkyl, . or a penta- or hexagonal heterocyclic radical optionally including another heteroatom]; or -X and X' together denote =N-R3 [R3 being optionally substituted C1-C5 alkyl] in racemic form and the corresponding enantiomers. 
<??>These new derivatives and their physiologically acceptable salts can be employed in therapeutics, especially in the treatment of metabolic disorders such as diabetes, obesities and their complications.
Patent DK-172065-B1 (DK)
Inventor: GRIES HEINZ
IPC: C07G99/00
Filed: 1984-07-30
Granted: 1997-10-13
Abstract: Diagnostic media suitable for NMR diagnoses contain compounds of Formula I    <IMAGE>  (I)  wherein   is a single bond or a double bond, X is the grouping -(CH2)n- or, if   is a single bond, also the grouping -NHCO(CH2)n- wherein n means 0 to 4, m means the numbers 0, 1, or 2, R1 is an alkyl residue substituted by hydroxy groups, acyloxy groups and/or alkylidenedioxy groups, R2 has the same meanings as R1 or is a hydrogen atom or an alkyl residue, R3 and R4 are alkyl residues, and R5 and R6 are alkyl residues optionally substituted by hydroxy groups.
Patent FI-101855-B1 (FI)
Inventor: PAYNE NICHOLAS IAN
IPC: A61K9/50
Filed: 1992-06-10
Granted: 1998-09-15
Abstract: A sustained release formulation of the anti-glaucoma drug acetazolamide with improved release characteristics, comprises substantially spherical, essentially binder-free pellets of the drug which are coated with a release-controlling membrane.
Patent FI-101727-B1 (FI)
Title: Steam chest in a cardboard or paper machine
Inventor: LINDSTROEM JAN
IPC: D21F7/00
Filed: 1996-12-31
Granted: 1998-08-14
Abstract: The invention concerns a steam chest for a paper or cardboard machine, said steam chest 10 comprising a steam chamber 11 to blow steam toward a paper or cardboard web and a suction zone 12 to prevent steam mist blown from the region of steam chamber 11 from spreading. A blowing nozzle 13 to create an air jet to prevent spreading of the steam mist and to ensure that the steam mist is fed to suction zone 12 is arranged on the outlet side of suction zone 12 in steam chest 10. <IMAGE>
Patent IE-57524-B1 (IE)
Title: Catheter for the treatment of constricted places,for example in a blood vessel
IPC: A61F2/958
Filed: 1986-04-28
Abstract: A catheter for opening constricted regions in the cardiovascular system includes an expandable dilatation zone comprising three dilatation elements arranged around a support tube. The dilatation elements are of tubular configuration, and each communicates at one end with a passage in the support tube leading to a pressure-suction pump. Constricted regions in the cardiovascular system may be enlarged or opened by introducing the dilatation zone into the affected site in a folded condition and expanding it peripherally therein. Upon expansion of the dilatation elements flow passages are formed between these elements, through which body fluid (for example blood) can pass with little resistance. The supply of body fluid to organs and tissues downstream of the affected site is thereby maintained. Interruption of the dilatation treatment is not required to insure this supply, thus permitting a substantial reduction in the overall duration of the medical procedure. The catheter may be employed, for example, to dilate blood vessels constricted by arteriosclerotic lesions and in valvuloplasty procedures, and may also be employed for treating constrictions in the esophagus.
Patent IE-47626-B1 (IE)
Title: 15-substituted-w-pentanorprostaglandin derivatives
IPC: A61K31/19
Filed: 1978-06-12
Abstract: 15-Substituted- omega -pentanorprostaglandin C-1 tetrazoles, imides and sulfonimides. Their use as anti-secretory agents or as agents for the control of fertility.
Patent IE-40643-B1 (IE)
Title: Equipment for milking parlours
IPC: A01J5/017
Filed: 1974-06-05
Abstract: Equipment for use in a milking parlor comprises cluster removal means, milk transfer means and sensing means for sensing cessation of milk flow. When milk flow ceases a signal is sent to the cluster removal means to effect cluster removal and a further signal is sent to the milk transfer means to transfer the milk from a receiver to a bulk storage vessel.
[US4005680A]
Patent IE-55298-B1 (IE)
Title: A space-divided optical switch assembly
IPC: H04Q3/52
Filed: 1984-05-30
Abstract: 1. A device for an optical spatial switching being accesses of a first group (GA) of N first distinct optical elements (fa) and a second group (GP) of P second distinct optical elements (fp), characterized in that it comprises : - an optical selection assembly (10) constituted by a stack of N rigid, flat optical plates (1) interposed and each maintained in a fixed position face to the access of one of the N first optical elements (fa) which are mounted according to the pitch of the optical plates (1) in their stack in a network which is transverse to these plates, each optical plate (1) in the assembly (10) comprising P distinct waveguides (g), first ends of which are coupled in common to the access of the first optical element which faces it and to which this optical plate is associated, second aligned ends of the P distinct waveguides (g) emerging on one of the edges, each optical plate being associated to an opaque tape (5, 7) presenting at least one perforation (I) and being movable in front of the second ends of the P waveguides of this optical plate, and all the optical plates (1) in this assembly having the second ends of their waveguides with their N tapes associated to the same side of the optical selection assembly (10), - an optical distribution assembly (20) constituted by a stack of P optical distribution plates (21) in which the plates (21) are mounted transversely to the optical plates (1) of the optical selection assembly (10) and at the same pitch as that between the second ends of the waveguides of each of the optical plates (1) of the optical selection assembly (10), and each one incorporating N individual waveguides (h) having their first ends coupled in common to the access of said second optical element (fp) to which the respective plate (21) is associated, whereas second aligned ends emerge on one of the edges of the plate, the first ends of the guides (h) of the different plates (21) being disposed at the same side of the stack and being coupled to the accesses of the second optical elements (fp), the second ends of the waveguides of the different plates (21) emerging at a common side of the stack and being arranged in N rows perpendicularly to the planes of the plates (21) of the distribution assembly, these second ends facing on each row second ends of the P waveguides respectively of one of said plates of the selection assembly (10) and being separated from said plate by the associated tape (5, 7).
[EP0131131A1]
Patent IE-55187-B1 (IE)
Title: Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases
IPC: A61K31/7064
Filed: 1983-06-13
Abstract: Pharmaceutical compositions which contain a xyloside or a lyxoside of a purine or pyrimidine base selected from the following compounds: 1-( beta -D-xylofuranosyl)-cytosine, 1-( beta -D-xylofuranosyl)-thymine, 9-( alpha -D-xylofuranosyl)-adenine, 9-( alpha -D-xylofuranosyl)-guanine, 1-( alpha -D-xylofuranosyl)-cytosine, 1-( alpha -D-xylofuranosyl)-thymine, 1-( beta -D-lyxofuranosyl)-adenine, 9-( beta -D-lyxofuranosyl)-guanine, 1-( beta -D-lyxofuranosyl)-cytosine, 1-( beta -D-lyxofuranosyl)-thymine, 9-( alpha -D-lyxofuranosyl)-adenine, 1-( alpha -D-lyxofuranosyl)-guanine, 1-( alpha -D-lyxofuranosyl)-cytosine and 1-( alpha -D-lyxofuranosyl)-thymine, have been found to be useful in therapy for treating various viral diseases.
[US4659698A]
Patent IE-63662-B1 (IE)
Title: Salts of azelastine having improved solubility
Inventor: HETTCHE HELMUTT DR
IPC: A61P29/00
Filed: 1990-05-04
Abstract: The present invention relates to salts of azelastine having improved solubility in water. The salts of the present invention are prepared by reacting azelastine with acetic acid, gluconic acid, lactic acid, or malic acid. The azelastine salts are effective in providing a cytoprotective effect.
Patent IE-45482-B1 (IE)
Title: Process for preparing substituted p-amino styrenes
IPC: C07C209/16
Filed: 1977-09-05
Abstract: A simple process for the preparation of beta -aminostyrenes proceeds from anilines by successively diazotizing, reacting with a vinyl ester, and reacting with a secondary amine without purification of the intermediate products. The compounds are reactive enamines useful in organic synthesis.
Patent IE-60889-B1 (IE)
Title: Laundry compositions
IPC: C11D3/37
Filed: 1987-07-14
Abstract: A laundry detergent or detergent additive composition comprising from about 0.1% to about 25% by weight of a soil-release polymer comprising ethyleneoxy terephthalate (EO-T) units and polyethyleneoxy terephthalate (PEO-T) units at a molar ratio (EO-T/PEO-T) of from about 0.5 to about 1.5, the PEO-T units containing polyethylene oxide (PEO) linking units having a molecular weight of from about 300 to about 3000, the molecular weight of the polymer being in the range from about 900 to about 9,000, and up to about 20% of a water-soluble quaternary ammonium surfactant. The composition provides excellent soil-release performance without detriment to clay-soil detergency and anti-deposition performance.
Patent IE-68310-B1 (IE)
Title: Method for producing native HIV gp160
Inventor: SARNGADHARAN MANGALASSERIL G
IPC: C07K1/22
Filed: 1989-08-14
Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp 160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III451, and grown in serum-free medium.
Patent IE-42369-B1 (IE)
Title: Peptide derivatives having an antihypertensive effect and process for their manufacture
IPC: C07K7/06
Filed: 1975-12-04
Abstract: 1536677 Heptapeptides/octapeptides HOECHST AG 20 Nov 1975 [5 Dec 1974] 47769/75 Heading C3H A peptide of general formula wherein Y represents a sarcosyl, succinamoyl or succinoyl radical: which may be prepared by the reaction of an N-protected sarcosine, or succinic acid monoamide or anhydride, or an activated ester of sarcosine or succinic acid with a peptide of formula and elimination of protective groups with an acid. The peptides (I) may be complexed either with zinc ions, and optionally, phosphate ions, wherein the complex is precipitated by adjustment of pH to 7À2 to 9, or with gelatine crosslinked with hexamethyleneisocyanate and polyphloretin phosphate. In the examples, peptides prepared are: succinamoyl - Arg - Val - Tyr - Val - His - Pro- C - Ph.Gly - OH; H - Sar - Arg - Val - Tyr - Val- His - Pro - C - Ph.Gly - OH. Peptide intermediates isolated are: OCTAPEPTIDE: Boc - Sar - Arg - Val - Tyr(But)- Val-His-Pro-C-Ph.Gly-OBut. HEPTAPEPTIDES: Succinamoyl - Arg- Val - Tyr(But) - Val - His - Pro - C - Ph.Gly- OBut; Z - Arg(Z 2 ) - Val - Tyr(But) - Val - His- Pro - C - Ph.Gly - OBut; H - Arg - Val - Tyr (But) - Val-His-Pro-C-Ph.Gly-OBut. HEXAPEPTIDES: Z and H - Val- Tyr(But)-Val-His-Pro-C-Ph.Gly-OBut. PENTAPEPTIDES: Z and H - Tyr(But)- Val-His-Pro-C-Ph.Gly-OBut. TETRAPEPTIDES: Z and H - Val - His- Pro-C-Ph.Gly-OBut. Dipeptide derivatives isolated are: Z-Val- His-OCH 3 and OH. Pharmaceutical compositions, which are preferably solutions in unit dosage form or, which have been lyophilized, comprise peptides (I) (unit dose of preferably 1 or 2 ml. which contains 6 to 100 mg. of peptide), the zinc with, optionally, phosphate complex thereof (unit dose of 1 ml. which contains 50 to 500 mcg. of the peptide), or the gelatine cross-linked with hexamethylene isocyanate/polyphloretin phosphate complex thereof (unit dosage of 50 to 500 mcg. of peptide) in admixture or conjunction with a pharmaceutically-acceptable carrier.
Patent IE-54266-B1 (IE)
Title: A salt of the (+)-isomer of flurbiprofen
IPC: C07C67/00
Filed: 1982-11-22
Abstract: The N-methyl-D-glucamine salt of (+)-2-(2-fluoro-4-biphenylyl)propionic acid, which is a novel compound with analgesic, anti-inflammatory and antipyretic properties and which is useful for treating inflammatory conditions including rheumatic disorders and as an analgesic. Pharmaceutical compositions containing the novel salt are also described. Also described are methods for preparing the novel salt by direct salification in an aqueous or non-aqueous medium, for example isopropanol, aqueous tetrahydrofuran, bis(methoxyethyl) ether and 4-methyl-1,3-dioxolan-2-one. Isopropanol is especially preferred.
Patent IE-56366-B1 (IE)
Title: Pharmaceutical compositions comprising an hydrogenated ergot alkaloid and heparin
IPC: A61P9/00
Filed: 1983-12-09
Abstract: Novel pharmaceutical compositions comprising i) an hydrogenated ergot alkaloid having vaso-constrictor activity, for example dihydroergotamine, or a pharmaceutically acceptable acid addition salt thereof and ii) a low molecular weight heparin or pharmaceutically acceptable salt thereof, and process for their production. Components ii) suitably have an average molecular weight of less than 10,000. The compositions are especially useful in the prevention of post-operative thrombosis.
Patent IE-71936-B1 (IE)
Title: Protection of a food cosmetic or pharmaceutical product against oxidation
Inventor: BRACCO UMBERTO
IPC: A23L29/00
Filed: 1990-09-28
Abstract: To protect an oxidation-sensitive fatty substance or a food, cosmetic or pharmaceutical product containing an oxidation-sensitive fatty substance, in particular an oil rich in polyunsaturated fatty acids, coenzyme Q is employed, if appropriate in combination with ascorbic acid and a natural emulsifier.
Patent IE-66561-B1 (IE)
Title: Quinoxaline compounds and their preparation and use
Inventor: HONORE TAGE
IPC: A61P25/20
Filed: 1989-11-24
Abstract: Heterocyclic dihydroxyquinoxaline compounds having the formula <CHEM>  wherein R<1> is hydroxy, alkoxy, aryloxy, aralkyloxy, cycloalkylalkoxy, cycloalkoxy, or acyloxy; and R<5>, R<6>, R<7> and R<8> independently are hydrogen, NO2, halogen, CN, SO2NR min R min , SO2R min , CF3, or OR min , wherein R min  is hydrogen or C1-4-alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.
Patent IE-67510-B1 (IE)
Title: IGF-I for treating adverse effect of steroid therapy
Inventor: GOLDBERG RONALD L
IPC: A61P5/38
Filed: 1990-12-21
Abstract: Methods of reducing or inhibiting some of the adverse effects of steroids by treatment with Insulin-like Growth Factor I (IGF-I) are disclosed along with compositions therefore, particularly in the area of cartilage and wound repair.
Patent LU-100319-B1 (LU)
Title: Mounting element for production of a dental prosthesis, a prosthesis and method of manufacturing same
Inventor: HORNBECK JACQUES
IPC: B33Y80/00
Filed: 2017-06-20
Granted: 2018-12-20
Abstract: The present invention concerns a mounting element (2) for a dental prosthesis (1), the prosthesis (1) including at least one bridge, the mounting element (2) and prosthesis (1) being formed using 3D printing. The mounting element (2) has an axis of elongation and comprises an engagement portion, for fixedly engaging the prosthesis (1) and an attachment portion (19), for enabling secure attachment of the prosthesis (1) to the jig (6) during machining. The mounting element (2) further comprises a registration portion (17) for aligning, in use, the prosthesis (1) in a precise position and/or orientation on a jig (6) during machining. The registration portion (17) preferably comprises a tapering portion, for example having a conically tapering outer surface (20) and/or at least one planar registration surface (11) extending parallel to the axis (14). The registration portion (17) may further comprise at least one planar inclined surface (21), continuous with the conically tapering outer surface (20), each inclined surface (21) being inclined relative to the axis (14) and intersecting a respective planar registration surface (11). The angle of taper of the tapering portion, the conically tapering outer surface (20) and/or angle of inclination of the inclined surface (21) relative to the axis (14) is c. 10 degrees. The mounting element (2) preferably further includes an open recess having, e.g., a T-shaped axial cross section though which, in use, a fixing element passes, for fixedly attaching the prosthesis (1) to the jig (6). A method of fabricating a dental prosthesis (1) and a dental prosthesis (1) are also disclosed.
Patent LU-103011-B1 (LU)
Title: Fuel cell performance optimization methodology combined with simulation and experiment
Inventor: ZHANG YANYI
IPC: H01M8/04992
Filed: 2022-09-20
Granted: 2023-03-20
Abstract: The present disclosure provides a fuel cell performance optimization methodology combined with simulation method and experimental method, comprising: with the mutual coupling of simulation and experiment, a fuel cell simulation model is established, a bench test is performed, the model Is calibrated, the operating conditions are refined and simulation and analysis are performed, and the optimal operating condition is obtained to perform the bench test, the optimal actual output voltage of the fuel cell is obtained, and the output voltage optimization result of the fuel cell are verified. The present disclosure not only reduces the number of experiments and experiment cycles in the process of fuel cell operation condition optimization, but also improves the reliability and accuracy of simulation results, and better plays the role of simulation in optimization.
Patent LU-502777-B1 (LU)
Title: Intelligent diagnosis and treatment method and system for tail gas of motor vehicle
Inventor: WANG YANG
IPC: G01N33/00
Filed: 2022-09-09
Granted: 2023-03-09
Abstract: The present invention discloses an intelligent diagnosis and treatment method and system for tail gas of a motor vehicle and relates to the technical field of treatment of tail gas of motor vehicles. The method comprises the following steps: S101, a data acquisition step: acquiring original tail gas detection data of a vehicle; S102, a fault diagnosis step: performing fault diagnosis on the acquired original tail gas detection data of the vehicle to obtain a diagnosis result and maintenance advice; and S103, a fault diagnosis result optimization step: acquiring the diagnosis result and the maintenance advice, and optimizing the diagnosis result and the maintenance advice in combination with historical diagnosis and maintenance records. The present invention solves the problem that tail gas of motor vehicles exceeding the standard cannot be rapidly and accurately diagnosed and treated in the prior art, thereby improving the diagnosis efficiency and the accuracy.
Patent NO-311767-B1 (NO)
Inventor: SIMON MARKUS M
IPC: C12P21/08
Filed: 1990-09-18
Abstract: Production of active vaccine against Lyme disease comprises (i) culturing E. coli cells that have been transformed with the sequence encoding the 31 kD OspA antigen of Borrelia burgdorferi; (ii) recovering the antigen as an unfused protein and (iii) optionally formulating it with usual carriers, fillers and auxiliaries.
Patent NO-303374-B1 (NO)
Inventor: LOWE LIONEL BARRY
IPC: A61K9/48
Filed: 1992-04-03
Abstract: A sustained release capsule adapted to be inserted into the rumen of a ruminant animal and means for retention of the capsule in the rumen. <??>A sustained release capsule (8) adapted to be inserted into the rumen of a ruminant animal through its oesophagus and retained within the rumen over a prolonged period to continuously deliver a biologically active composition (32) carried in the capsule (8), comprising an elongated tubular body (10) comprising a tube (16) and an end cap (12) secured to one end thereof for substantially enclosing the biologically active composition (32), the other end of the capsule (8) being a delivery end (18), the body (10) having an opening (20) at the delivery end (18) of the capsule (8) for delivery of the composition (32) to the rumen, and a plurality of retention arms (44) attached to or formed integrally with the cap (12), the arms (44) being adapted to extend outwardly from the cap (12) for retaining the capsule (8) in the rumen, the arms (44) being resilient to enable them to bend from their outwardly extending positions toward the body (10) so that they lie alongside the body (10) allowing the capsule (8) to be inserted through the animal's oesophagus, the resilient arms (44) normally extending from the body (10) at an angle between 75 DEG  and 90 DEG  with respect to the axis of the tubular body (10), and for each arm (44) said cap (12) has an external curved surface (26) disposed with respect to the arm (44) so that when the arm (44) is bent toward the body (10), the arm (44) contacts the curved surface (26) and the curved surface (26) controls the bending of the arm (44) so that the arm (44) does not bend abruptly, said arms (44) being adapted to return to their outwardly extending positions when the capsule (8) reaches the rumen, characterised in that said cap (12) is secured to said one end by means of at least two circumferential beads (30) having at least one sealing ring (31) located therebetween. <IMAGE>